Research programme: Pseudomonas aeruginosa vaccine - Syntiron

Drug Profile

Research programme: Pseudomonas aeruginosa vaccine - Syntiron

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntiron
  • Class Bacterial vaccines; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pseudomonal infections

Highest Development Phases

  • Research Pseudomonal infections

Most Recent Events

  • 23 Jan 2018 Pseudomonas aeruginosa vaccine - Syntiron is available for licensing as of 23 Jan 2018. (Syntiron pipeline, January 2018)
  • 23 Jan 2018 Early research in Pseudomonal infections in USA (unspecified route) (Syntiron pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top